ADAP Medical Advisory Committee

March 30, 2022 Meeting Notes

1) Welcome and Rollcall

I. Welcome:

Meeting opened by Sharisse Kemp, ADAP Branch Chief

II. Introductions:

MAC Members, CDPH and Magellan introduced themselves

MAC Members in Attendance Stephen O'Brien, Michelle Sherman, Danny Toub, Lucas Hill, David Grelotti, Laveeza Bhatti, David Lewis, Cliff Okada, Arlet Arratoonian, Joanna Eveland, Wilbert Jordan, Glenn San Agustin <u>CDPH/Office of AIDS staff in Attendance</u> Philip Peters, Sharisse Kemp, Ann Nakamura, Becca Parks, James Vo

MAC Members not in Attendance Jennefer Yoon

Magellan Representatives in Attendance Jason Eugenio, Carrie Holden

2) ADAP / MAC Updates

- I. Medications added to the ADAP formulary:
 - Generic Seroquel added to the ADAP formulary.
 - Removal of brand preferencing policy for antiretrovirals.
 - Expanded reimbursement for Cabenuva, ADAP funding will be used to reimburse the injection administration fee and clinic visits for approved clinical providers.
- II. Medications removed from the ADAP formulary
 - None
- III. Update on the medications discussed during the January 2021 MAC meeting:
 - Hypertension, oral contraceptives, and opportunistic infection medications are currently being reviewed.

3) Medication Discussion

- I. No New ARVs have received FDA approval
- II. Cabenuva (Cabotegravir/Rilpivirine)

- Lucas Hill (Presentation): Review of Long-Acting Injection Cabotegravir/Rilpivirine and Real-World Experience
- III. No public comments received

4) **Opportunistic Infection Treatments**

- Eric Tang (presentation): CA-ADAP Medical Advisory Committee: STI treatment PrEP-AP formulary review
- John Openshaw (presentation): COVID-19 outpatient therapeutics

5) Magellan Rx Presentation

• Carrie Holden (presentation): Hold until next MAC meeting

6) Close of Meeting

I. The next ADAP MAC meeting is scheduled for July 20, 2022, from 7:30 a.m. to 9:00 a.m.

7) Action Items

Action Items	Owners
Discussion of Islatravir and diabetes treatment at the next MAC meeting in July.	Dr. Peters/James Vo